Appili Therapeutics is developing novel approaches to lead the fight against infectious disease. Despite numerous achievements in the development of anti-infectives, infectious disease remains the leading cause of death worldwide. While historically there have been many alternative antibiotics available for treatment of bacterial infections, today the development of antibiotics has slowed dramatically.
Appili Therapeutics is developing cutting edge strategies to bring new classes of antibiotics and anti-infectives to the clinic to improve treatment and health of patients suffering from infection.
Appili Therapeutics was founded in 2015 by a team of drug development, infectious disease, and commercialization experts to advance the global fight against infectious disease and the mounting threat of drug-resistant pathogens.